TNFSF13 and systemic lupus erythematosus: Another dual BAFF/APRIL inhibitor, atacicept, has also been studied in SLE with SRI-4 response rates at week 24 ranging from 53.8 to 57.8% versus 44.0% in placebo groups (22).